肺结核
跳跃
结核分枝杆菌
医学
大流行
疾病
重症监护医学
传染病(医学专业)
免疫学
2019年冠状病毒病(COVID-19)
病理
业务
财务
作者
Rachel L. Kinsella,Dennis Zhu,Gregory A. Harrison,Anne E. Mayer Bridwell,Jerome Prusa,Sthefany M. Chavez,Christina L. Stallings
出处
期刊:Annual Review of Pathology-mechanisms of Disease
[Annual Reviews]
日期:2021-01-24
卷期号:16 (1): 377-408
被引量:33
标识
DOI:10.1146/annurev-pathol-042120-032916
摘要
Mycobacterium tuberculosis ( Mtb), the causative agent of tuberculosis (TB), remains a leading cause of death due to infection in humans. To more effectively combat this pandemic, many aspects of TB control must be developed, including better point of care diagnostics, shorter and safer drug regimens, and a protective vaccine. To address all these areas of need, better understanding of the pathogen, host responses, and clinical manifestations of the disease is required. Recently, the application of cutting-edge technologies to the study of Mtb pathogenesis has resulted in significant advances in basic biology, vaccine development, and antibiotic discovery. This leaves us in an exciting era of Mtb research in which our understanding of this deadly infection is improving at a faster rate than ever, and renews hope in our fight to end TB. In this review, we reflect on what is known regarding Mtb pathogenesis, highlighting recent breakthroughs that will provide leverage for the next leaps forward in the field.
科研通智能强力驱动
Strongly Powered by AbleSci AI